Search results for "Administration"

showing 10 items of 5106 documents

Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma

2012

Oral metronomic chemotherapy is a therapeutic option which is particularly attractive due to its ease of administration and low toxic burden. Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens.A retrospective analysis of 61 patients with advanced breast carcinoma was carried out with the aim of reporting activity in terms of response rate, control of tumor-related symptoms, outcome, and toxicity. All patients had hormonal therapy-resistant metastatic disease and had previously received two lines of chemotherapy. The first cohort of 22 patients received oral cyclophosphamide …

AdultAged 80 and overAntineoplastic Combined Chemotherapy ProtocolNeoplasms Hormone-DependentSettore MED/06 - Oncologia MedicaPalliative CareAdministration OralBreast NeoplasmsMiddle AgedDisease-Free SurvivalDrug Administration ScheduleCohort StudiesMethotrexateAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCohort StudieAntineoplastic Agents AlkylatingCyclophosphamideBreast NeoplasmAgedHumanNeoplasm StagingRetrospective Studies
researchProduct

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-i…

2010

Abstract OBJECTIVE: To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy, as the role of maintenance in intravesical chemotherapy is debated. PATIENTS AND METHODS: Between May 2002 and August 2003, 577 patients with non-muscle-invasive bladder cancer (NMI-BC) underwent transurethral resection (TUR) and early intravesical chemotherapy (epirubicin, 80 mg/50 mL). They were randomized between a 6-week induction cycle and the induction cycle plus maintenance with 10 monthly instillations. In all, 95 patients with T1G3, Tis or single and primary Ta-T1 G1-G2 tumours were excluded; 482 patients at intermediate risk of recurrence continued the study.…

AdultAged 80 and overMaleAntibiotics AntineoplasticRemission InductionCystoscopyintravesical chemotherapy bladder carcinomaMiddle AgedCombined Modality TherapySettore MED/24 - UrologiaAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsHumansFemaleNeoplasm Recurrence LocalEpidemiologic MethodsAgedEpirubicin
researchProduct

The influence of apo E phenotypes on the plasma triglycerides response to hormonal replacement therapy during the menopause

2001

Objective: To study the influence of apo E phenotype in plasma lipids, especially in triglycerides levels, in menopausal women receiving hormonal replacement therapy (HRT). Methods: One hundred and ten postmenopausal women were studied. Plasma total cholesterol (TC), HDL-C and triglycerides (TG) were measured before and after 3 months of HRT and the apo E phenotype was determined. According to the apo E phenotype the sample was divided into three groups: E2/E3 (n=28), E3/E3 (n=96) and E4/E3 (n=25). Results: In the pre-treatment state, higher plasma levels of TC and TC/HDL-C ratio were observed in women with phenotype E3/E4 (P<0.0001 and P<0.02, respectively), while higher plasma TG levels w…

AdultApolipoprotein EMedroxyprogesteronemedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classmedicine.medical_treatmentAdministration OralAdministration CutaneousWhite PeopleGeneral Biochemistry Genetics and Molecular BiologyCohort StudiesApolipoproteins EPolymorphism (computer science)Internal medicinemedicineHumansProspective StudiesTriglyceridesChemotherapyEstradiolbusiness.industryCholesterol HDLHormonal replacement therapyObstetrics and GynecologyMiddle Agedmedicine.diseasePhenotypeMenopauseCholesterolPhenotypeEndocrinologyCardiovascular DiseasesSpainEstrogenFemaleMenopausebusinessPharmacogeneticsMaturitas
researchProduct

New Modes of Regulation for Health and Safety: Post-Enlargement Policy Perspectives for the European Union

2006

The recent joining of ten new member states to the European Union, eight of which are former communist countries, has reopened inherent tensions in current European Union (EU) policy-making on safety and health in the workplace. These spring from seemingly incompatible objectives; the need to ensure broad EU member state compliance with regulation, around agreed minimum standards through active regulatory enforcement, and the promotion of “softer” voluntary initiatives in the management of workplace risks and hazards in order to create “a culture of prevention.” The present EU strategy which ends in 2006, seeks to secure a balance between both sets of objectives. However, with respect to t…

AdultBaltic StatesEmploymentMaleRisk AssessmentEuropean studiesData Protection DirectiveRisk FactorsPolitical scienceEuropean integration050602 political science & public administrationAccidents OccupationalHumansSingle Euro Payments Areamedia_common.cataloged_instance0501 psychology and cognitive sciencesEuropean UnionEuropean unionOccupational Health050107 human factorsmedia_commonMarketingEuropean Union lawData CollectionHealth Policy05 social sciencesCommunity ParticipationGeneral MedicineFiscal union0506 political scienceEuropeOccupational DiseasesPolitical economyFemaleForecastingSoft lawNEW SOLUTIONS: A Journal of Environmental and Occupational Health Policy
researchProduct

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

2016

OBJECTIVE To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone. RESEARCH DESIGN AND METHODS In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide was administered once daily at any time of the day. Lixisenatide was administered once daily within 1 h prior to the morning or evening meal. RESULTS At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference −0.62% [95% CI −0.8; −0.4]; P &amp;…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyHypoglycemiaDrug Administration Schedulelaw.inventionYoung Adult03 medical and health sciencesLixisenatidechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineClinical endpointHumansHypoglycemic AgentsAgedGlycemicAged 80 and overGlycated HemoglobinAdvanced and Specialized NursingLiraglutidebusiness.industryBody WeightLiraglutideMiddle AgedPostprandial Periodmedicine.diseaseHypoglycemiaMetforminMetforminTreatment OutcomeEndocrinologyDiabetes Mellitus Type 2chemistryDrug Therapy CombinationFemalePeptidesbusinessmedicine.drugDiabetes Care
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Effects of sorbinicate and nicotinic acid on blood viscosity, red cell deformation and platelet function

1982

Summary Nicotinic acid (NA) and a retard derivative, sorbinicate, were investigated for their effects on blood rheology and platelet function, after oral administration, in two groups of patients with lower limb atherosclerosis obliterans — the second group having diabetes also. Red cell deformation and blood plasma viscosity were studied in the nondiabetic group (single dose of NA, 100 mg, and sorbinicate, 400 mg); release of platelet malondialdehyde (MDA) (single dose of NA, 100 mg, and sorbinicate, 800 mg), and the platelet regeneration time (before and after sorbinicate 400 mg × 3/die for 7 days) were studied in the diabetic group. Both drugs induced a significant improvement in red cel…

AdultBlood PlateletsMalemedicine.medical_specialtyErythrocytesTime FactorsBlood viscosityNiacinchemistry.chemical_compoundNEFAOral administrationMalondialdehydeInternal medicineDiabetes mellitusBlood plasmamedicineHumansSorbitolPlateletTriglyceridesPharmacologyRed CellChemistryNicotinic AcidsFibrinogenMiddle AgedBlood Viscositymedicine.diseaseMalondialdehydeCholesterolEndocrinologyBiochemistryFemalePharmacological Research Communications
researchProduct

Effects of cigarette smoking or ingestion of nicotine on platelet 5-hydroxytryptamine (5-HT) levels in smokers and non-smokers.

1992

Platelets of healthy smokers and non-smokers were prepared and their content of 5-hydroxytryptamine was determined by HPLC with electrochemical detection. Platelet 5-HT levels in smokers (728 +/- 156 pmol per 10(8) platelets, mean +/- SEM, n = 9) were significantly higher than those in non-smokers (353 +/- 156 pmol per 10(8) platelets, n = 11). Smoking of a single cigarette caused a transient increase in platelet 5-HT levels by about 350% in non-smokers, but had no additional effect in smokers. Similarly, chewing of nicotine gum (4-8 mg nicotine) resulted in a transient increase in platelet 5-HT by about 100% in non-smokers, but not in smokers. In conclusion, smoking of cigarettes can cause…

AdultBlood Plateletsmedicine.medical_specialtyNicotineSerotoninAdministration OralReceptors NicotinicNicotine03 medical and health sciences0302 clinical medicineCigarette smokingInternal medicineDrug DiscoverymedicineEnterochromaffin CellsIngestionHumansPlateletReceptorGenetics (clinical)5-HT receptorbusiness.industrySmokingGeneral Medicinerespiratory tract diseases3. Good healthEndocrinologyNicotine gum030220 oncology & carcinogenesisReceptors Serotoninbehavior and behavior mechanismsMolecular MedicineSerotoninbusiness030217 neurology & neurosurgerymedicine.drugThe Clinical investigator
researchProduct

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with plati…

2004

OBJECTIVES: There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1…

AdultBridged-Ring Compoundsmedicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPharmacologyNeutropeniaGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansExatecanEnzyme InhibitorsAgedOvarian NeoplasmsChemotherapyTaxanebusiness.industryObstetrics and GynecologyExatecan mesylateMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicDrug Resistance MultipleRegimenOncologychemistryDrug Resistance NeoplasmCamptothecinFemaleTaxoidsTopoisomerase I InhibitorsbusinessOvarian cancer
researchProduct

The A allele of cluster of differentiation 36 (CD36) SNP 1761667 associates with decreased lipid taste perception in obese Tunisian women.

2015

Recent studies have suggested that excessive intake of dietary fat is associated with obesity. Some obese subjects have been reported to exhibit high thresholds for the gustatory detection of lipids via lipid receptors, such as cluster of differentiation 36 (CD36). We studied lingual detection thresholds for emulsions containing oleic acid in obese Tunisian women (n203) using a three-alternative forced choice (3-AFC) method. Genotyping of theTNF-α(rs1800629),IL-6(rs1800795) andCD36(rs1761667) genes was performed to associate with lipid taste perception thresholds. TheCD36genotype distribution was as follows: GG (n42), AG (n102) and AA (n59). Women with theCD36GG genotype exhibited oral dete…

AdultCD36 AntigensTastemedicine.medical_specialtyTunisiaGenotypeCD36Medicine (miscellaneous)Administration OralBiologyPolymorphism Single Nucleotidechemistry.chemical_compoundFood PreferencesInternal medicineGenotypemedicineSNPCluster AnalysisHumansObesityAllele10. No inequalityGenotypingAllelesGeneticsNutrition and DieteticsInterleukin-6Tumor Necrosis Factor-alphaTaste PerceptionMiddle Agedmedicine.diseaseTaste BudsObesityDietary FatsOleic acidEndocrinologychemistryTastebiology.proteinFemaleOleic AcidThe British journal of nutrition
researchProduct